1 – 20 of 59
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
(
- Contribution to journal › Scientific review
-
Mark
The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers
(
- Contribution to journal › Scientific review
-
Mark
Brain injury markers in blood associate with generalised oedema on computed tomography after cardiac arrest
(
- Contribution to conference › Abstract
- 2020
-
Mark
Quantification of total apolipoprotein e and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases
(
- Contribution to journal › Article
- 2019
-
Mark
Neurogranin as a potential synaptic marker in the cerebrospinal fluid of patients with a first episode psychosis
(
- Contribution to journal › Letter
- 2017
-
Mark
Reduced cerebrospinal fluid concentration of interleukin-12/23 subunit p40 in patients with cognitive impairment
(
- Contribution to journal › Article
- 2016
-
Mark
Cerebrospinal fluid-induced retardation of amyloid β aggregation correlates with Alzheimer's disease and the APOE ε4 allele
(
- Contribution to journal › Article
- 2015
-
Mark
Cerebrospinal fluid substance P concentrations are elevated in patients with Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
(
- Contribution to journal › Article
-
Mark
Increased Cerebrospinal Fluid Level of Insulin-like Growth Factor-II in Male Patients with Alzheimer's Disease
(
- Contribution to journal › Article
- 2014
-
Mark
The amyloid-β degradation pattern in plasma: A possible tool for clinical trials in Alzheimer's disease
(
- Contribution to journal › Article
- 2013
-
Mark
Serum but not Cerebrospinal Fluid levels of Insulin-Like Growth Factor-I (IGF-I) and IGF-Binding Protein-3 (IGFBP-3) are Increased in Alzheimer ́s Disease
2013) Endokrindagarna, 2013(
- Contribution to conference › Poster
- 2012
-
Mark
Age and diagnostic performance of Alzheimer disease CSF biomarkers
(
- Contribution to journal › Article
- 2011
-
Mark
Discriminatory analysis of biochip-derived protein patterns in CSF and plasma in neurodegenerative diseases
(
- Contribution to journal › Article
- 2010
-
Mark
Changes in cerebrospinal fluid insulin during non-neurological surgery
2010) 23rd Congress Meeting of European-College-of-Neuropsychopharmacology In European Neuropsychopharmacology 20. p.328-329(
- Contribution to journal › Published meeting abstract
-
Mark
An enzyme activity as a potential biomarker for Alzheimer's disease.
2010) Alzheimer's Association International Conference on Alzheimer's Disease 2010 In Alzheimer's & Dementia 6(4). p.497-498(
- Contribution to journal › Published meeting abstract
-
Mark
The stability of AQT processing speed, ADAS-Cog and MMSE during acetylcholinesterase inhibitor treatment in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Convergence of chromogranin and amyloid metabolism in the brain.
2010) Alzheimer's Association International Conference on Alzheimer's Disease 2010 In Alzheimer's & Dementia 6(4). p.511-511(
- Contribution to journal › Published meeting abstract
- 2009
-
Mark
Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?
(
- Contribution to journal › Article